Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Talampicillin is an orally administered beta-lactam antibiotic from the penicillin family. It is a prodrug of ampicillin, designed to improve oral absorption and bioavailability compared to ampicillin itself. After oral administration, it is rapidly absorbed and hydrolyzed by tissue esterases in the intestinal wall to release active ampicillin and 2-hydroxymethyl-benzoic acid; no unchanged talampicillin appears in peripheral blood. Its mechanism of action involves inhibition of bacterial cell wall synthesis by targeting penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death. Talampicillin was developed as an acid-stable alternative for oral use but has not been approved by the FDA for use in the United States[1][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on talampicillin.